Insider Trading Alert - LCI, EL And CI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 20, 2014, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $712.40 to $14,201,355.08.

Highlighted Stocks Traded by Insiders:

Lannett (LCI) - FREE Research Report

Bedrosian Arthur P, who is President and CEO at Lannett, sold 5,000 shares at $41.30 on Aug. 20, 2014. Following this transaction, the President and CEO owned 643,817 shares meaning that the stake was reduced by 0.77% with the 5,000-share transaction.

Farber David, who is 10% Owner at Lannett, sold 5,000 shares at $41.30 on Aug. 20, 2014. Following this transaction, the 10% Owner owned 75,870 shares meaning that the stake was reduced by 6.18% with the 5,000-share transaction.

The shares most recently traded at $35.39, down $5.91, or 16.7% since the insider transaction. Historical insider transactions for Lannett go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 23,500
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 33,500

The average volume for Lannett has been 687,500 shares per day over the past 30 days. Lannett has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 10.63% year-to-date as of the close of trading on Wednesday.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company has a P/E ratio of 33.4. Currently, there are 4 analysts who rate Lannett a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCI - FREE

TheStreet Quant Ratings rates Lannett as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Lannett Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Estee Lauder Cos (EL) - FREE Research Report

Trower Alexandra C., who is EVP - Global Communications at Estee Lauder Cos, sold 15,344 shares at $76.63 on Aug. 20, 2014. Following this transaction, the EVP - Global Communications owned 10,179 shares meaning that the stake was reduced by 60.12% with the 15,344-share transaction.

The shares most recently traded at $76.61, down $0.02, or 0.03% since the insider transaction. Historical insider transactions for Estee Lauder Cos go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 28,500

The average volume for Estee Lauder Cos has been 1.5 million shares per day over the past 30 days. Estee Lauder Cos has a market cap of $17.9 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 1.67% year-to-date as of the close of trading on Wednesday.

The Estee Lauder Companies Inc. manufactures, markets, and sells skin care, makeup, fragrance, and hair care products worldwide. The stock currently has a dividend yield of 1.04%. The company has a P/E ratio of 25.1. Currently, there are 12 analysts who rate Estee Lauder Cos a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EL - FREE

TheStreet Quant Ratings rates Estee Lauder Cos as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Estee Lauder Cos Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cigna (CI) - FREE Research Report

Sadler Jason D, who is Pres., International Markets at Cigna, sold 11,000 shares at $93.02 on Aug. 20, 2014. Following this transaction, the Pres., International Markets owned 16,787 shares meaning that the stake was reduced by 39.59% with the 11,000-share transaction.

The shares most recently traded at $94.11, up $1.09, or 1.15% since the insider transaction. Historical insider transactions for Cigna go as follows:

  • 4-Week # shares sold: 5,983
  • 12-Week # shares sold: 33,042
  • 24-Week # shares sold: 187,926

The average volume for Cigna has been 1.5 million shares per day over the past 30 days. Cigna has a market cap of $24.7 billion and is part of the health care sector and health services industry. Shares are up 7.4% year-to-date as of the close of trading on Wednesday.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The stock currently has a dividend yield of 0.04%. The company has a P/E ratio of 12.9. Currently, there are 8 analysts who rate Cigna a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CI - FREE

TheStreet Quant Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Cigna Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers